TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
07 Maggio 2024 - 1:00PM
Business Wire
– Accomplished industry veteran brings deep
strategic and operational expertise
TriSalus Life Sciences® Inc. (Nasdaq: TLSI), an oncology company
integrating its novel delivery technology with immunotherapy to
transform treatment for patients with liver and pancreatic tumors,
announced today the appointment of Liselotte Hyveled to its Board
of Directors. Ms. Hyveled brings over two decades of experience
stimulating scientific innovation and advancing pharmaceutical
pipelines through research and development excellence.
“We are thrilled to welcome Liselotte to the TriSalus Board of
Directors as we commercialize the TriNav® Infusion System and
progress our pipeline through key milestones in 2024 and beyond,”
said Mats Wahlstrom, TriSalus Chairman of the Board. “Her wealth of
experience and strategic insights will be instrumental in shaping
TriSalus' long-term vision of pioneering innovative treatments for
liver and pancreatic cancers. We eagerly anticipate Liselotte's
contributions to our continued success.”
“Liselotte's extensive background in fostering patient-centric
innovations, strategic planning, and the integration of technology
and therapeutics will be invaluable assets as we navigate TriSalus’
growth trajectory,” Mary Szela, President and CEO of TriSalus. “Her
guidance will be pivotal in our efforts to expand and scale
operations while expediting the development of our technology and
therapeutic pipelines.”
Ms. Hyveled is a seasoned executive with over two decades of
successfully implementing innovative solutions for challenging
chronic diseases within a rapidly changing, highly competitive
R&D environment. Currently serving as the Chief Patient Officer
at Novo Nordisk, she is responsible for ensuring the integration of
patient needs and perspectives into the company's decision-making
processes and operations, from inception to commercialization. Ms.
Hyveled's tenure at Novo Nordisk has been marked by numerous
leadership positions and contributions, reflecting her commitment
to R&D excellence, breakthrough innovation and advancing
patient-centric solutions. She has initiated several social
responsibility initiatives at Novo Nordisk with a focus on
neurodiversity, disabilities and generational intelligence. Ms.
Hyveled holds a Master of Pharmacy Science from Copenhagen
University and a Master of Medical Business Strategies from
Copenhagen Business School.
Ms. Hyveled commented, “TriSalus has developed a truly
groundbreaking platform aimed at addressing the complexities of
liver and pancreatic cancers, positioning itself for a pivotal
phase of expansion. I am honored to collaborate with the TriSalus
board and leadership team to build upon the company's achievements
and realize its vision of transforming patient outcomes.”
About TriSalus Life Sciences
TriSalus Life Sciences® is an oncology focused medical
technology business providing disruptive drug delivery technology
with the goal of improving therapeutics delivery to liver and
pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion for the pancreas. The PEDD
approach modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. Nelitolimod, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors and which can make current immunotherapies ineffective
in the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that nelitolimod delivered via PEDD may have
favorable immune effects within the liver and systemically. The
target for nelitolimod, TLR9, is expressed across cancer types and
the mechanical barriers addressed by PEDD are commonly present as
well. Nelitolimod delivered by PEDD will be studied across several
indications in an effort to address immune dysfunction and overcome
drug delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on X (formerly Twitter) and
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240507764267/en/
For Media and Investor Inquiries: Argot Partners
212.600.1902 TriSalus@argotpartners.com
Grafico Azioni TriSalus Life Sciences (NASDAQ:TLSI)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni TriSalus Life Sciences (NASDAQ:TLSI)
Storico
Da Feb 2024 a Feb 2025
